Affiliations 

  • 1 Gastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France
  • 2 Plateforme Bioinformatique Gilles Thomas, Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France
  • 3 Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France
  • 4 Apoptosis, Cancer and Development (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France
  • 5 Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Chirurgie Digestive, Lyon, France
  • 6 Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
  • 7 Netris Pharma, Lyon, France
  • 8 TGF-beta and Immune Response (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Equipe labellisée Ligue nationale contre le cancer, Cancer Research Center of Lyon, Lyon, France
  • 9 Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
  • 10 Gastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France. thomas.walter@chu-lyon.fr
  • 11 Gastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France. benjamin.gibert@lyon.unicancer.fr
Nat Commun, 2025 Mar 04;16(1):2197.
PMID: 40038310 DOI: 10.1038/s41467-025-57305-8

Abstract

Small intestinal neuroendocrine tumors (siNETs) are rare bowel tumors arising from malignant enteroendocrine cells, which normally regulate digestion throughout the intestine. Though infrequent, their incidence is rising through better diagnosis, fostering research into their origin and treatment. To date, siNETs are considered to be a single entity and are clinically treated as such. Here, by performing a multi-omics analysis of siNETs, we unveil four distinct molecular groups with strong clinical relevance and provide a resource to study their origin and clinical features. Transcriptomic, genetic and DNA methylation profiles identify two groups linked to distinct enteroendocrine differentiation patterns, another with a strong immune phenotype, and the last with mesenchymal properties. This latter subtype displays the worst prognosis and resistance to treatments in line with infiltration of cancer-associated fibroblasts. These data provide insights into the origin and diversity of these rare diseases, in the hope of improving clinical research into their management.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.